Meloxicam

Quick links to important sections

Meloxicam

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meloxicam

What is Meloxicam?

Meloxicam is a prescription medication belonging to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). It is primarily used to manage symptoms associated with various types of arthritis and other inflammatory conditions.

Therapeutic Purpose

The medication is designed to reduce pain, swelling, and stiffness in the joints. By targeting the underlying mechanisms of inflammation, meloxicam helps improve physical function and mobility for individuals living with chronic joint discomfort.

Mechanism of Action

Meloxicam works by blocking the activity of certain enzymes in the body, specifically cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). These enzymes play a critical role in the production of prostaglandins, which are chemicals that signal pain and promote inflammation at the site of injury or disease. By inhibiting these enzymes, meloxicam lowers prostaglandin levels, thereby decreasing the inflammatory response.

Common Applications

This medication is frequently utilized for the long-term management of several conditions, including:

  • Osteoarthritis: A degenerative joint disease caused by the breakdown of cartilage.
  • Rheumatoid Arthritis: An autoimmune disorder where the immune system attacks the joints.
  • Juvenile Rheumatoid Arthritis: A form of arthritis that affects children and adolescents.

Unlike some other NSAIDs that require multiple daily doses, meloxicam is characterized by a long half-life, which typically allows for consistent levels of the medication in the bloodstream throughout the day.

Regulatory References

  1. Meloxicam Drug Information (NIH MedlinePlus)

What side effects are possible with Meloxicam?

Possible Side Effects and Safety Information

The safety profile for Meloxicam is officially documented and structured according to the adverse effects reported in clinical studies and post-marketing surveillance, consistent with the Nonsteroidal Anti-inflammatory Drug (NSAID) class.

Official Regulatory Classifications

Adverse reactions are classified by frequency and by the affected organ system, known as System-Organ Classes (SOCs). Reactions frequently reported and classified as Common (ge1%) include gastrointestinal issues like dyspepsia (indigestion), diarrhea, abdominal pain, nausea, and vomiting, along with nervous system effects such as headache and dizziness. Less frequent, or Uncommon, effects may include transient elevated liver enzymes and somnolence.

Serious Documented Adverse Reactions

Regulatory documentation highlights serious, potentially fatal risks. These include Serious Cardiovascular Thrombotic Events such as myocardial infarction and stroke, which may occur early in treatment and can increase with the duration of use. Similarly, Serious Gastrointestinal Adverse Events—bleeding, ulceration, and perforation of the stomach or intestines—can occur at any point during therapy without warning symptoms. Additionally, rare but life-threatening Serious Cutaneous Reactions, including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are documented.

Safety Constraints and Special Populations

Specific restrictions define the safe use of Meloxicam. It is contraindicated for treating pain immediately following Coronary Artery Bypass Graft (CABG) surgery. Furthermore, use is avoided at 30 weeks gestation and later due to the risk of premature closure of the fetal ductus arteriosus. Older adults are specifically noted to be at a higher risk for serious gastrointestinal adverse events.

Overdose and Emergency Response

Meloxicam overdose information, as documented in official regulatory sources, describes a range of possible manifestations and mandatory emergency actions. Initial symptoms following an acute overdose are often limited and generally reversible with supportive care. These may include non-specific gastrointestinal and central nervous system effects such as nausea, vomiting, epigastric pain, lethargy, and drowsiness. Gastrointestinal bleeding may also occur.

In cases of severe poisoning, the official documentation warns of the potential for life-threatening outcomes. These severe manifestations include acute renal failure, hepatic dysfunction, and serious cardiovascular events such as cardiovascular collapse and cardiac arrest. Neurological complications, including convulsions and coma, as well as respiratory depression, are also documented risks. Anaphylactoid reactions may also be present.

Due to these severe potential risks, immediate medical attention is required for any suspected overdose. Regulatory instructions emphasize that there is no known specific antidote for Meloxicam poisoning. Management must be restricted to symptomatic and supportive care. Official procedural guidance outlines measures such as gastric evacuation and the administration of activated charcoal to reduce absorption. Furthermore, the use of Cholestyramine is an officially described measure demonstrated to accelerate the drug’s elimination.

Therapeutic Uses of Meloxicam

What Meloxicam Treats: Main Uses and Benefits

The medication is commonly used to provide symptomatic support across several conditions presenting with systemic or localized discomfort. It is applicable across therapeutic domains where chronic or acute inflammation creates noticeable physiological strain.

Symptomatic Management of Chronic Arthritic Pain

Meloxicam is used to help with symptoms that become more disruptive during flare-ups in conditions presenting with systemic or localized discomfort. It is used to address conditions involving episodic or fluctuating manifestations, including Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, and Juvenile Idiopathic Arthritis (JIA). It is also relevant in clinical settings where additional symptomatic support is needed, such as managing moderate-to-severe pain in post-operative care and addressing systemic manifestations like fever.

“Offers symptomatic relief that helps patients cope more steadily, and may assist with maintaining functional stability.”

This commonly used support helps improve day-to-day comfort during symptomatic periods, and is commonly used for both adult and relevant pediatric patient groups experiencing persistent symptoms.

Quick Fact: Symptomatic Support Focus
Primary Focus Symptomatic management of pain and stiffness in conditions involving inflammatory or irritative processes.
Key Benefit Provides supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Population Eligibility and Contraindications

Official regulatory guidelines define specific populations permitted to use meloxicam and several groups for whom use is strictly prohibited. The medicine is primarily approved for use in adults for conditions like Osteoarthritis and Rheumatoid Arthritis. It is also approved for pediatric patients aged 2 years and older but only for the treatment of Juvenile Idiopathic Arthritis (JIA).

Use is absolutely contraindicated for patients who have experienced allergic-type reactions (such as asthma or hives) after taking aspirin or any other NSAID. It must not be used by individuals with active gastrointestinal bleeding or peptic ulceration, those with severe, uncontrolled heart failure, or individuals with severe non-dialyzed hepatic or renal impairment.

Furthermore, meloxicam is contraindicated for the treatment of pain following coronary artery bypass graft (CABG) surgery and must not be used during the third trimester of pregnancy (after 30 weeks gestation). Use is also not recommended during lactation due to its excretion in human milk. Older adults are advised to use the lowest effective dosage due to a heightened risk of serious adverse reactions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Meloxicam's official regulatory documentation outlines specific interaction patterns based on combined pharmacodynamic and pharmacokinetic effects, defining necessary restrictions and cautions for co-administration. These documented interactions focus strictly on formal outcomes such as increased toxicity or diminished efficacy.

Prohibited and High-Risk Combinations

Co-administration with analgesic doses of Aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs) is generally not recommended due to a significantly increased risk of serious gastrointestinal events. Meloxicam is officially contraindicated for the treatment of pain in the immediate period following Coronary Artery Bypass Graft (CABG) surgery. A specific product restriction notes that the oral suspension formulation is contraindicated for use with Sodium Polystyrene Sulfonate.

Interactions Affecting Drug Exposure and Toxicity

Use with certain medicines can lead to increased plasma concentrations of the co-administered drug. This includes Lithium and Methotrexate, where documented interference with renal clearance increases the risk of toxicity. Co-administration with Cyclosporine may also increase the risk of nephrotoxicity. Grapefruit juice is documented as potentially increasing meloxicam exposure via a metabolic pathway.

Interactions Affecting Efficacy and Bleeding Risk

A significant increased risk of bleeding is documented when Meloxicam is combined with medications that affect blood clotting, such as Anticoagulants, Antiplatelet agents, and Oral Corticosteroids. Furthermore, Meloxicam may diminish the antihypertensive effect of medicines like ACE Inhibitors and Diuretics. Specific caution regarding worsened renal function is noted for elderly or volume-depleted patients co-administering these agents. Interactions with substances like Alcohol are also formally documented.

Mechanism of Action

The Mechanism of Action of Meloxicam

Preferential Inhibition of the COX-2 Enzyme

Meloxicam acts by preferentially inhibiting the Cyclooxygenase-2 (COX-2) enzyme, the core biological target that generates pro-inflammatory chemical messengers. By reversibly binding to this enzyme, the drug suppresses its function, which is the initial step in the body's Arachidonic Acid Cascade that generates pro-inflammatory mediators.

Molecular Cascade to Physiological Modulation

The inhibition of COX-2 leads directly to a sharp reduction in the synthesis of pro-inflammatory Prostaglandins (PGE2). This molecular blockade modifies systemic signaling by attenuating the concentration of chemical messengers that promote the inflammatory response and sensitize peripheral nociceptors. A similar action occurs centrally to modulate the body's thermoregulatory set point, resulting in predictable physiological adjustments that lead to temperature reduction.

️ Concentration-Dependent Mechanistic Constraint

The mechanism operates under a key constraint: while it favors COX-2, this preference is diminished at high concentrations, leading to increased inhibition of the constitutive COX-1 enzyme. This constraint affects the mechanistic profile, as COX-1 governs baseline physiological functions, and its inhibition alters the balance of prostanoid synthesis across multiple systems.

Dosage and Administration Information

Official Administration Guidelines

Meloxicam is administered through oral and intravenous (IV) routes. The fundamental guideline is to use the lowest effective dose for the shortest duration consistent with individual treatment goals.

Standard Dosing and Frequency

Regimen Focus Starting Dose Maximum Daily Dose Frequency
Oral (Adults) 7.5 mg 15 mg Once daily
Intravenous (IV) 30 mg 30 mg Once daily

Oral therapy is typically initiated at 7.5 mg once daily and may be increased to 15 mg if needed based on response. IV administration, restricted to acute settings, is given as a 30 mg bolus injection over 15 seconds, and patients must be well hydrated prior to administration.

Administration Instructions and Adjustments

  • Oral Intake: Tablets and capsules may be taken with water or liquid, and without strict regard to the timing of meals. The oral suspension must be shaken well before each use.
  • Population-Specific Rules: For patients on hemodialysis due to renal impairment, the maximum daily oral dose is restricted to 7.5 mg. For children aged 2 years and older with Juvenile Idiopathic Arthritis (JIA), dosing is calculated by body weight (e.g., 0.125 mg/kg once daily) up to a 7.5 mg maximum.
  • Procedural Caution: Different oral formulations (e.g., tablet vs. suspension) are not considered interchangeable, even if the total milligram strength is identical.

How to Handle a Missed Dose

Official labeling directs that if a dose is missed, it should be skipped, and the patient should resume the regular once-daily dosing schedule with the next scheduled dose. Double doses should not be taken to compensate.

Recent Clinical Evidence

Meloxicam: Overview of Studies and Research Evidence


Evidence Base for Osteoarthritis and Rheumatoid Arthritis

Research examined conditions characterized by fluctuating manifestations like Osteoarthritis (OA) and Rheumatoid Arthritis (RA). Studies monitored patient-reported outcomes describing perceived discomfort, such as standardized pain scales and indices for physical function. Data show patterns related to these outcomes over observation periods, with some trials monitoring persistence of assessed outcomes for up to 18 months in RA. However, long-term effects are not fully established beyond the trial periods. Research focused on changes in symptoms, providing limited information concerning any effects on the underlying progression of the condition itself.


Evidence Base for Ankylosing Spondylitis

The research for Meloxicam in Ankylosing Spondylitis (AS) was evaluated in prospective, controlled clinical trials involving adults with active AS. These studies examined outcomes related to systemic or functional imbalance and used specialized disease activity indices. Studies monitored outcomes capturing phases of heightened symptom activity, tracking the percentage of participants who met protocol-defined criteria over defined time intervals. Patterns related to symptoms were better documented over longer follow-up periods lasting up to a year, rather than just initial short-term assessments.


Evidence in Pediatric Patients with Juvenile Idiopathic Arthritis (JIA)

Meloxicam was studied for use in pediatric patients (children aged 2 to 16 years) with the oligo-course and poly-course forms of Juvenile Idiopathic Arthritis (JIA). Research utilized controlled trials to monitor outcomes capturing phases of heightened symptom activity by using specialized pediatric criteria. Studies reported how symptoms evolved in the observed populations. It is important to note that results apply only to the populations studied (excluding systemic JIA), and evidence for effects beyond the one-year study period is limited in the controlled trial literature.


Long-Term Research Gaps and Areas of Uncertainty

The clinical evidence landscape often relies on open-label extension studies to examine the durability of responses. Key limitations noted across the research include that follow-up durations were limited in many primary efficacy studies. Furthermore, the research approach was almost exclusively focused on outcomes linked to inflammatory states and patient-reported physical discomfort, rather than underlying disease modification. As such, research provides context but not individual predictions, and the results describe group patterns, not personal outcomes.

Key Studies & References

  1. Meloxicam Drug Information

Frequently Asked Questions (FAQ)

Common questions about Meloxicam (FAQ)


Q: Is Meloxicam the same kind of drug as ibuprofen?

Meloxicam is a type of nonsteroidal anti-inflammatory drug (NSAID) described as having preferential activity toward the Cyclooxygenase-2 (COX-2) enzyme. Ibuprofen is also an NSAID, but it is generally classified as a non-selective inhibitor. While both are used to address pain and inflammation, this difference in how they affect the body's enzymes is noted in official pharmacological texts.


Q: How is Meloxicam different from Celebrex?

Meloxicam and Celebrex (celecoxib) are both NSAIDs used to help relieve symptoms of pain and inflammation. Official documents describe both as acting on the COX-2 enzyme. The key difference in their classification is that Meloxicam is described as having preferential COX-2 inhibition, while Celebrex is described as being a highly selective COX-2 inhibitor.


Q: How long does it usually take for Meloxicam to start working?

Information suggests that the effects of Meloxicam may start to provide noticeable pain relief within approximately 30 to 60 minutes after being administered. A consistent level in the body is generally reached after several days of regular administration.


Q: Is the long-term use of Meloxicam generally studied?

Clinical trials for certain conditions like rheumatoid arthritis have examined the effects of Meloxicam use over periods up to 18 months. Regulatory documents emphasize the principle of using the lowest effective amount for the shortest duration.


Q: Why is Meloxicam sometimes given only once a day?

Meloxicam is often prescribed to be taken once daily because of its pharmacokinetic profile. Official information shows that the drug has a relatively long elimination half-life of approximately 20 hours. This property supports the use of a once-daily dosing regimen.


Q: Is there a maximum amount of time Meloxicam is usually prescribed for?

Official guidelines emphasize that the drug should be used for the shortest duration consistent with individual treatment goals. The labeling does not specify a single, universal maximum duration for all conditions, but regulatory information for this class of medicine focuses on the principle of minimizing the overall duration of use.


Q: Does Meloxicam cause drowsiness or fatigue?

Official regulatory documents list somnolence (drowsiness) as an uncommon side effect. Fatigue, or a general feeling of tiredness, is also noted in various post-marketing reports or in the common adverse effects sections.


Q: Does Meloxicam interact with herbal supplements?

Official documents note that interactions may occur with nonprescription products or substances that affect blood clotting. Specific herbal supplements are generally not individually detailed in the primary regulatory labeling.


Q: Can Meloxicam be prescribed for back pain?

The official regulatory documents list Meloxicam's approved indications as the relief of signs and symptoms of Osteoarthritis, Rheumatoid Arthritis, and Juvenile Idiopathic Arthritis. Official labeling does not list back pain as a formal, approved indication.


Q: Can Meloxicam be used for menstrual cramps?

The official regulatory documents list Meloxicam's approved indications as the relief of signs and symptoms of Osteoarthritis, Rheumatoid Arthritis, and Juvenile Idiopathic Arthritis. Menstrual cramps (primary dysmenorrhea) are not listed as an official approved indication.


Q: Can people with a history of heart attack use Meloxicam?

Meloxicam carries a serious warning about the risk of cardiovascular thrombotic events, including myocardial infarction (heart attack). Official information states the drug's use requires extreme caution in populations with a history of cardiovascular disease. The drug is often noted as being generally avoided in these circumstances.


Q: Does Meloxicam cause swelling in the hands or feet?

Yes, official safety documents indicate that edema (fluid retention or swelling) and peripheral edema (swelling of the ankles, feet, or hands) have been reported as side effects associated with Meloxicam use.


Q: Can Meloxicam cause changes in mood?

While uncommon, various effects on the central nervous system have been reported with Meloxicam. Some safety reports have included cases of mood changes or psychiatric symptoms.


Q: Does Meloxicam affect blood sugar levels?

Official documents note a potential for drug interactions when Meloxicam is used concomitantly with certain oral hypoglycemic agents (medications used to manage blood sugar). The labeling notes the potential for interaction, indicating that monitoring of blood sugar levels may be necessary.


Q: Can Meloxicam be taken by someone who has asthma?

Meloxicam is contraindicated (must not be used) in patients who have a history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. This restriction is based on the documented risk of severe allergic-type reactions in this population.


Q: What are the signs of a serious skin reaction to Meloxicam?

Serious skin reactions like Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN) are rare but documented risks. These reactions may begin with symptoms like fever, flu-like symptoms, or a skin rash that is red or purple and may blister or peel.


Q: What does regulatory information say about Meloxicam and driving?

Regulatory patient information often describes that if a person experiences side effects such as dizziness, drowsiness, vertigo, or visual disturbances, driving or operating machinery should be avoided.


Q: Does Meloxicam affect fertility or conception?

Regulatory documents state that Meloxicam, like other drugs that inhibit prostaglandin synthesis, may impair female fertility. For this reason, its use is generally noted as being avoided for women who are actively trying to conceive or are undergoing an investigation for infertility.


Q: Do you need a prescription to get Meloxicam?

Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that is typically available only with a prescription from a healthcare provider. This status is generally due to the potential for serious side effects that are outlined in the regulatory documents.


Q: Is the difference between Meloxicam and a COX-2 inhibitor?

There is no difference in class; Meloxicam is described by official documentation as belonging to the chemical class of Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and specifically as a drug with preferential inhibition of the Cyclooxygenase-2 (COX-2) enzyme.

How should Meloxicam be stored and disposed of?

Official Storage and Disposal Guidelines

Meloxicam must be stored strictly according to the conditions defined in regulatory labeling to maintain stability. The product requires storage at Controlled Room Temperature, specifically between 20 to 25 C (68 to 77 F). The medicine must be kept in a tight, closed container and protected from environmental factors including heat, freezing, moisture, and direct light.

All meloxicam products must be stored out of the reach of children. For disposal, do not flush unused or expired medicine down a sink or toilet. The officially preferred method is using a drug take-back program. If no take-back option is available, the medicine may be mixed with an undesirable substance (e.g., dirt) and sealed in a container before being placed in household trash, as documented by the FDA.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Meloxicam found in:

A-Z Index: